| Name | Title | Contact Details |
|---|
M2 Communications is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
About Arrhythmia Research Technology, Inc. The Company through itswholly-owned subsidiary, Micron Products, Inc. manufacturescomponents, devices and equipment primarily for the medical anddefense industries. Micron is engaged in the production and sale ofsilver/silver chloride coated and conductive resin sensors used ascomponent parts in the manufacture of integrated disposableelectrophysiological sensors. These disposable medical devices areused worldwide in the monitoring of electrical signals in variousmedical applications. The Company has expanded into customthermoplastic injection molded products with a full array of design,engineering and production services and management. The addition ofan orthopedic implant machining operation produces quick-turn, highvolume and patient-specific, finished orthopedic implants. TheCompany also has developed and distributes a customizable proprietarysignal-averaging electrocardiography (SAECG) software used in thedetection of certain heart arrhythmias and that is reconfigurable fora variety of hardware platforms.
NovoLogix is a cutting-edge Medical Pharmacy Benefit Management company.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Real-time PCR testing for everyone Watch the video Amplifying human potential through real-time PCR It all starts with a single sample. Add chemistry, heat, and light to make the fragments of a single virus visible by amplification up to a billion fold...